Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: SusieQ1065 who wrote (11705)	8/21/2001 8:20:32 AM
From: 2MAR$	Respond to of 208838

Myriad Genetics fiscal Q4 loss narrows -9c vs -10c SALT LAKE CITY, Aug 21 (Reuters) - Biotechnology firm Myriad Genetics Inc. <MYGN.O> on Tuesday reported a narrower fourth-quarter loss, as its total revenues climbed. The Salt Lake City, Utah-based company, which studies genes and proteins to develop drug therapies, posted a net loss for the quarter ended June 30 of $2.2 million, or 9 cents a share, compared with a loss of $2.6 million, or 12 cents, in the year-earlier period. Analysts expected the firm to post a loss in a range of 7 cents to 12 cents per share, or 10 cents a share on average, according to 10 brokers polled by Thomson Financial/First Call. Total product revenue for the latest quarter climbed to $10.8 million from $9.2 million a year earlier. "During the past year, Myriad moved well down the path towards becoming a leading biopharmaceutical product company," President and Chief Executive Officer Peter Meldrum said in a statement. "The company now has a prostate cancer drug in human clinical trials and a full pre-clinical drug pipeline that represents an exciting opportunity to move several breakthrough products into the clinic over the coming year." ((-- Los Angeles bureau + 1 213 380 2014))